Additional drug shows promise for women with triple-negative breast cancer
In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators reported at the 2013 San Antonio Breast Cancer Symposium. The study, sponsored by the Cancer and Leukemia Group B, includes authors from the Dana-Farber Cancer Institute, Brown University, the University of Texas MD Anderson Cancer Center, the UNC Lineberger Comprehensive Cancer Center. New York University, Washington University in St. Louis, City of Hope Comprehensive Cancer Center, and Mount Sinai Medical Center.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.